Microfracture for glenohumeral cartilage defects: Short- to mid-term results. A systematic review and meta-analysis.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 42473631.
- Also identified by DOI 10.1177/17585732261469823 and PMC identifier 13380649.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Articular cartilage defects of the glenohumeral joint are challenging in young, active patients, where microfracture-a common first-line marrow-stimulation technique-has uncertain efficacy and long-term durability in the shoulder. This study evaluates the clinical outcomes of patients undergoing treatment with microfracture for chondral lesions of the glenohumeral joint. A systematic review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Embase, and Cochrane Library were searched through January 2026. Patient-reported outcomes (PROs), reoperation rates, complications, and radiographic outcomes were assessed. Eight Level IV studies comprising 171 shoulders met the inclusion criteria. Mean age was 50.4 years with a 97.5-month follow-up. Significant improvements occurred in the American Shoulder and Elbow Score (+20.3 points), Visual Analogue Scale for pain (-2.2 points), and Single Assessment Numeric Evaluation scores. Pooled reoperation rate was 20.9% (95% CI 14.2-29.7%). No procedure-related complications were reported. Two studies noted radiographic progression of osteoarthritis despite clinical improvement. Microfracture provides consistent short- to mid-term improvements in PROs and appears safe for glenohumeral cartilage defects. However, the evidence is limited to Level IV studies, and concerns remain regarding long-term durability and progression of osteoarthritis.